20/20 Biolabs, Inc. Common Stock (AIDX)vsAstraZeneca PLC (AZN)
AIDX
20/20 Biolabs, Inc. Common Stock
$1.49
-1.97%
HEALTHCARE · Cap: $15.62M
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2872082% more annual revenue ($58.74B vs $2.05M). AZN leads profitability with a 17.4% profit margin vs -182.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AIDX
Avoid15
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
+4.0%
Fair Value
$214.34
Current Price
$184.74
$29.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.8B in free cash flow
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -503.0% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
AIDX has a balanced fundamental profile.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : AIDX
The primary concerns for AIDX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
AIDX profiles as a turnaround stock while AZN is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 15/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (ticker: AIDX) is a forward-thinking biotechnology company dedicated to advancing genomic research and diagnostics through innovative laboratory services. By focusing on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is at the forefront of molecular diagnostics. With a strong commitment to harnessing cutting-edge technologies, 20/20 Biolabs is well-positioned to lead the charge in personalized medicine as the demand for genomic data accelerates. The company’s strategic initiatives and robust market positioning signal a promising growth trajectory in the dynamic biotechnology sector.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?